Skip to content

VIKING THERAPEUTICS, INC.

VKTX

CIK 0001607678

← back to feed
Revenue (TTM)
$0
Q1 Apr 2026
Net Income (TTM)
−$360.3M
−227.1% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$3.17
−215.8% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
—
Q1 Apr 2026
Net Margin
—
Q1 Apr 2026
Free Cash Flow (TTM)
—
Q1 Apr 2026
Cash
$118.12M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
116.11M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings